Covid-19 manufacturing roundup: As the US government bags another 100M doses of Moderna shot, the biotech is chipping in on UAE rollout
President Joe Biden’s administration has ordered another round of shots.
Moderna and the US government have reached a deal that will provide the company with another 200 million doses of its Covid-19 vaccine, and include the option to purchase other candidates from the company’s pipeline, Moderna announced Wednesday. The agreement brings the total number of Moderna shots to 500 million. Another 110 million will be delivered in Q4 of 2021 and 90 million are expected in Q1 of 2021.
As of June 14, the US has received 217 million doses from Moderna.
“We appreciate the collaboration with the U.S government for these additional doses of the Moderna COVID-19 vaccine, which could be used for primary vaccination, including of children, or possibly as a booster if that becomes necessary to continue to defeat the pandemic,” CEO Stéphane Bancel said in a press release.
Moderna tag teams with private investors to bump up UAE vaccine rollout
Tiny UAE is the global leader in per capita terms, and now, it’s getting a boost from Moderna and a national investment company to help distribute the vaccine and future booster shots once authorized.
Magenta Investments, a pharmaceutical and healthcare company that is a part of a UAE investment and industrial conglomerate, announced plans to distribute the shots in 2021 and 2022. The company is a major player in improving health in the Middle East and Africa, it said, and is a part of Mawarid Holding Investment and the Emirates Business Group.
“We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE,” Moderna CCO Corinne Le Goff said in a statement. “Together with our partners, we hope to advance our goal to expand access to our vaccine globally, and support governments such as the UAE in protecting their citizens, residents and visitors against the pandemic.”
The announcement comes in the middle of a push from Moderna to expand its footprint across the globe, as it looks to supply areas in need with vaccines and boosters. UAE neighbor Saudi Arabia has lagged behind in getting doses in the arms of its people, and Friday, Moderna announced that it will manufacture its vaccine and boosters on Saudi soil.
Since a pledge to produce as many as 3 billion doses of its vaccine per year, Moderna announced partnerships to manufacture vaccines in Spain, South Korea, Australia and Switzerland, as well as bolstered its US operations with expansions in Massachusetts. CEO Stéphane Bancel announced that his company will donate 500 million doses to Gavi, the vaccine alliance. Last Thursday, Moderna filed for emergency use authorization to get its vaccine in the arms of teens between the ages of 12 and 17. Earlier that week, it filed for authorization with EU and Canadian regulators as well.
Recipharm plan in France approved for Moderna’s Covid-19 production
The EMA has approved a new manufacturing site for Moderna’s Covid-19 vaccine.
A Recipharm plant in Monts, France will produce the finished product, and alternative sites from Moderna in Norwood, MA and Lonza in Portsmouth, NH have also been approved. The updates are expected to produce between 1 and 2 million doses of the vaccine for the European market each month.